Patents Examined by Maury Audet
  • Patent number: 10183981
    Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: January 22, 2019
    Inventors: Songnian Lin, Lin Yan, Pei Huo, Dmitri Pissarnitski, Danqing Feng, Ravi Nargund, Yuping Zhu, Ahmet Kekec, Christina B. Madsen-Duggan, Zhi-Cai Shi, Zhicai Wu, Yingjun Mu
  • Patent number: 10144944
    Abstract: Polypeptide preparations having target levels of glycans, and methods of producing such polypeptide preparations using putrescine, are described.
    Type: Grant
    Filed: April 25, 2017
    Date of Patent: December 4, 2018
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventor: Holly Prentice
  • Patent number: 10138485
    Abstract: Neutral lipid formulations for nucleic acid delivery are provided according to the invention. The neutral lipid formulations include hydrophobically modified polynucleotides and fat mixtures. Methods of using the neutral lipid formulations are also provided.
    Type: Grant
    Filed: September 22, 2009
    Date of Patent: November 27, 2018
    Assignee: RXi Pharmaceuticals Corporation
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, Michelle Miller, Karen G. Bulock
  • Patent number: 10130677
    Abstract: The invention relates to antimicrobial peptides, pharmaceutical compositions comprising the peptides and to uses thereof for in the treatment or prevention of microbial, bacterial, fungal, viral and parasitic infection.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: November 20, 2018
    Assignees: Academisch Ziekenhuis Leiden h.o.d.n. LUMC, Academisch Medisch Centrum
    Inventors: Petrus Hendricus Nibbering, Anna de Breij, Robert Alexander Cordfunke, Sebastianus Antonius Johannes Zaat, Jan Wouter Drijfhout
  • Patent number: 10112980
    Abstract: The invention discloses a polypeptide with improved alkaline stability, which polypeptide comprises a mutant of a B or C domain of Staphylococcus Protein A (SpA), as specified by SEQ ID NO 1 or SEQ ID NO 2, or of Protein Z, as specified by SEQ ID NO 3, wherein at least the glutamic acid residue at position 15 has been mutated to an amino acid other than asparagine. The invention also discloses multimers of said polypeptide, as well as separation matrices comprising the multimers or polypeptides.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: October 30, 2018
    Assignee: GE HEALTHCARE BIOPROCESS R&D AB
    Inventors: Mats Ander, Goran Bauren, Tomas Bjorkman, Gustav Rodrigo
  • Patent number: 10098967
    Abstract: Disclosed are conjugates of hydrophobic drugs linked to protected or unprotected amino acids or peptides. The disclosed conjugates are amphiphilic and can self assemble into nantubes. Nanotubes comprising the conjugates are also described and can have high loading of the drug and protect it from degradation or elimination. The nanotubes are well suited to deliver hydrophobic and unstable drugs to individuals.
    Type: Grant
    Filed: December 3, 2013
    Date of Patent: October 16, 2018
    Assignees: Ohio State Innovation Foundation, Trustees of Boston University
    Inventors: Jonathan R. Parquette, Se Hye Kim, Mark W. Grinstaff, Jonah A. Kaplan
  • Patent number: 10098925
    Abstract: The present invention relates to a protein comprising SEQ ID NO:1 (mature form of SLURP-1) and to a composition comprising the same for use in inducing or accelerating cicatrization, and/or in preventing infection in the eye of a subject.
    Type: Grant
    Filed: December 9, 2013
    Date of Patent: October 16, 2018
    Assignee: Brightpulse Holding Ltd.
    Inventors: Jean-Marc Combette, Catherine Deloche, Claire Abadie, Sebastien Mouz, Julien Perino
  • Patent number: 10072041
    Abstract: Method for preparing a peptide assembly of n fragments and n?1 amino acids bearing a thiol function, represented by the formula: A1-C1-A2-C2-A3- . . . -Ci?1-Ai- . . . -Cn?1-An??(I) in which A1, A2, A3, . . . Ai . . . , An are peptide fragments, C1, C2, C3 . . . Ci?1 . . . Cn?1 are amino acid residues bearing a thiol function, n is comprised between 3 and 50, and i is 2 to n, in which a peptide-thioester is prepared of formula: A1-SR (II) in which A1 is a peptide fragment and SR is an alkyl thioester residue, R being alkyl optionally substituted, starting from a bis(2-sulphanylethyl)amino peptide.
    Type: Grant
    Filed: February 15, 2012
    Date of Patent: September 11, 2018
    Assignees: Centre National de la Recherche Scientifique, Universite de Lille 1 Sciences et Technologies
    Inventors: Oleg Melnyk, Nathalie Ollivier, Reda Mhidia, Julien Dheur
  • Patent number: 10072048
    Abstract: Provided are astexin-1, astexin-2 and astexin-3 lasso peptides, which are based on sequences identified in Asticaccaulis excentricus, and methods of making and using same. Astexin-1 is highly polar, in contrast to many lasso peptides that are primarily hydrophobic, and has modest antimicrobial activity against Caulobacter crescentus, a bacterium related to Asticaccaulis excentricus. The solution structure of astexin-1 was determined, revealing a unique topology that is stabilized by hydrogen bonding between segments of the peptide. Astexins-2 and -3 are intracellular lasso peptides.
    Type: Grant
    Filed: August 29, 2013
    Date of Patent: September 11, 2018
    Assignee: THE TRUSTEES OF PRINCETON UNIVERSITY
    Inventors: A. James Link, Mikhail O. Maksimov
  • Patent number: 10072055
    Abstract: Polypeptides having homology to regions of the N-terminal 50 residues of human Annexin 1 are provided for medical use as anti-inflammatory agents. Some of the polypeptides have homology to the N-terminal 48 residues of human Annexin 1, especially to residues 2-48 and 11-48 thereof. In some embodiments, properties of these compounds are improved by at least one modification at residues corresponding to residues 11, 22, 25 and/or 36 of human Annexin 1, and/or by C-terminal amidation of the polypeptide. Analogs of amino acids 2-26 of human Annexin 1, especially acetylated at the N-terminus and/or amidated at the C-terminus and having modifications at 11 and/or 22 are also disclosed for medical use as anti-inflammatory agents.
    Type: Grant
    Filed: July 20, 2015
    Date of Patent: September 11, 2018
    Assignee: Resother Pharma APS
    Inventors: Angelo P. Consalvo, Nozer M. Mehta, Mauro Perretti, Jesmond Dalli
  • Patent number: 10017556
    Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: July 10, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Songnian Lin, Lin Yan, Pei Huo, Dmitri Pissarnitski, Danqing Feng, Ravi Nargund, Yuping Zhu, Ahmet Kekec, Christina B. Madsen-Duggan, Zhi-Cai Shi, Zhicai Wu, Yingjun Mu
  • Patent number: 10004828
    Abstract: Novel peptide-based hydrogels, composed of short aromatic peptides (e.g., homodipeptides of aromatic amino acid residues) are disclosed. The hydrogels are characterized by remarkable rigidity and biocompatibility. Further disclosed are uses of these hydrogels in applications such as tissue engineering, drug delivery, cosmetics, implantation, packaging and the like. Further disclosed are processes and kits for preparing these hydrogels.
    Type: Grant
    Filed: October 15, 2006
    Date of Patent: June 26, 2018
    Assignee: Romat at Tel-Aviv University Ltd.
    Inventors: Ehud Gazit, Assaf Mahler, Meital Reches
  • Patent number: 10004784
    Abstract: The invention concerns the use of hepcidin for the diagnosis and therapy of disorders of iron homeostasis. Hepcidin can be used in the treatment of disorders resulting from iron overload while inhibitors of hepcidin can be used in the treatment of anaemia.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: June 26, 2018
    Assignee: Institut National de la Sante et de la Recherche Medicale
    Inventors: Gael Nicolas, Sophie Vaulont, Axel Kahn
  • Patent number: 9974840
    Abstract: The present invention provides compositions comprising human placental telopeptide collagen, methods of preparing the compositions, methods of their use and kits comprising the compositions. The compositions, kits and methods are useful, for example, for augmenting or replacing tissue of a mammal.
    Type: Grant
    Filed: September 11, 2013
    Date of Patent: May 22, 2018
    Assignee: Celularity, Inc.
    Inventors: Mohit Bhatia, Chris Lugo, Qian Ye, James W. Edinger
  • Patent number: 9957295
    Abstract: Disclosed are pharmaceutical compositions comprising a CIRP inhibitor. Methods of treating a subject suffering from an inflammatory condition comprising administering to said subject a CIRP inhibitor are also described herein.
    Type: Grant
    Filed: September 24, 2014
    Date of Patent: May 1, 2018
    Assignee: The Feinstein Institute for Medical Research
    Inventor: Ping Wang
  • Patent number: 9957330
    Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for carbonic anhydrase IX (CAIX), and provides a CAIX binding polypeptide comprising the sequence EX2X3X4AX6X7EIX10X11LPN?LX16X17X18QX20?X21AFIX25X26LWD. The present disclosure also relates to the use of such a CAIX binding polypeptide as a diagnostic, prognostic agent and/or therapeutic agent.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: May 1, 2018
    Assignee: AFFIBODY AB
    Inventors: Lars Abrahmsén, Ingmarie Höidén-Guthenberg, Elin Gunneriusson
  • Patent number: 9920096
    Abstract: The present invention relates generally to novel biological and purified peptides as bradykinin receptor modulators for use in the treatment and/or prevention of inflammatory diseases, pain, hyperalgesia, cardiovascular and/or cerebral ischemic diseases, in a subject in need thereof.
    Type: Grant
    Filed: June 24, 2014
    Date of Patent: March 20, 2018
    Inventor: Jair Ribeiro Chagas
  • Patent number: 9902761
    Abstract: We describe an ELABELA polypeptide comprising a sequence CXXXRCXXXHSRVPFP (SEQ ID NO: 1), in which X signifies an amino acid residue, such as a sequence selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 18, preferably CLQRRCMPLHSRVPFP (SEQ ID NO: 2), or a fragment, homologue, variant or derivative thereof, which polypeptide is capable of maintaining self-renewal and/or pluripotency of a stem cell.
    Type: Grant
    Filed: December 3, 2014
    Date of Patent: February 27, 2018
    Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR)
    Inventor: Bruno Reversade
  • Patent number: 9896486
    Abstract: A polypeptide with improved alkaline stability, which polypeptide comprises a mutant of a B or C domain of Staphylococcus Protein A, as specified by SEQ ID NO 1 or SEQ ID NO 2, or of Protein Z, as specified by SEQ ID NO 3, wherein at least the glutamine residue at position 9 has been mutated to an amino acid other than asparagine. The invention also discloses multimers of said polypeptide, as well as separation matrices comprising the multimers or polypeptides.
    Type: Grant
    Filed: July 8, 2014
    Date of Patent: February 20, 2018
    Assignee: GE Healthcare BioProcess R&D AB
    Inventors: Gustav Rodrigo, Mats Ander, Tomas Bjorkman, Goran Bauren
  • Patent number: 9895424
    Abstract: Stabilized pharmaceutical formulations of insulin analogs and/or insulin derivatives are disclosed.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: February 20, 2018
    Assignee: SANOFI
    Inventors: Oliver Bley, Petra Loos, Bernd Bidlingmaier, Walter Kamm, Harald Berchtold